Abstract
The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Current Pharmaceutical Design
Title: Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs
Volume: 8 Issue: 13
Author(s): Thomas J. Dougherty, John F. Barrett and Michael J. Pucci
Affiliation:
Keywords: microbial genomics, antibiotic discovery, prokaryotic drug, genomics approach, genomics-based drug
Abstract: The process of prokaryotic drug discovery has been a model of success for over fifty years, yet the number of exploited bacterial targets is a mere fraction, less than 0.1% of the potential targets (based on total number of bacterial genes identified by gene sequence projects). To better understand the potential for drug intervention, multiple paradigms have been established in the pharmaceutical industry, all with some semblance of commonality and uniqueness to provide proprietary positioning, yet no company has been successful to date in taking a ‘genomics approach’ to the finish line of having a genomics-based drug on the market. Within this overview, we provide a strategic overview of a sample process for the identification, validation and exploitation of novel antibacterial targets ascertained through a bioinformatics-based genomics drug discovery program.
Export Options
About this article
Cite this article as:
Dougherty J. Thomas, Barrett F. John and Pucci J. Michael, Microbial Genomics and Novel Antibiotic Discovery: New Technology to Search for New Drugs, Current Pharmaceutical Design 2002; 8 (13) . https://dx.doi.org/10.2174/1381612023394782
DOI https://dx.doi.org/10.2174/1381612023394782 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tau Phosphorylation and Aggregation as a Therapeutic Target in Tauopathies
CNS & Neurological Disorders - Drug Targets The TLR9 Antagonist iCpG-ODN at Different Dosages Inhibits Cerebral Ischemia/Reperfusion Injury in Mice
CNS & Neurological Disorders - Drug Targets Pro-Drugs for Indirect Cannabinoids as Therapeutic Agents
Current Drug Delivery Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)
Current Neuropharmacology Gonadal Hormones in Adolescent Females with β-Thalassemia in Relation to Iron Load
Endocrine, Metabolic & Immune Disorders - Drug Targets Brain Inflammation Following Intracerebral Hemorrhage
Current Neuropharmacology The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets From Nature to Drug Discovery: The Indole Scaffold as a ‘Privileged Structure’
Mini-Reviews in Medicinal Chemistry Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research Reprogramming of B Cells into Regulatory Cells with Engineered Fusokines
Infectious Disorders - Drug Targets Inhibitors of Catechol-O-Methyltransferase
CNS & Neurological Disorders - Drug Targets Nalmefene: A Novel Drug for an Old Disorder
Current Medicinal Chemistry Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry MIIP, a Cytoskeleton Regulator that Blocks Cell Migration and Invasion, Delays Mitosis, and Suppresses Tumorogenesis
Current Protein & Peptide Science Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Hypothalamic and Neuroendocrine Changes in Huntingtons Disease
Current Drug Targets Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry Current Drug Targets for Antihyperlipidemic Therapy
Mini-Reviews in Medicinal Chemistry Voltage-Gated Sodium Channels: Mutations, Channelopathies and Targets
Current Medicinal Chemistry Dehalogenative and Deprotonative Lithiation of Pyridines: A Second Wind for Trimethylsilylmethylithium (TMSCH2Li)
Current Organic Chemistry